Hypertensive emergency: Difference between revisions

 
(112 intermediate revisions by 19 users not shown)
Line 1: Line 1:
==Diagnosis==
''High blood pressure without symptoms is NOT hypertensive emergency (see [[asymptomatic hypertension]])''


* End-organ damage 2/2 increased BP (generally >180/120, usually > 220/130)
==Background==
** Brain - Encephelopathy, seizure, ICH, ischemic stroke
*Definition: end-organ damage due to hypertension
** Eyes - Retinal hemorrhage, exudate, papilledema
**Blood pressure is generally >180/120 (usually > 220/130), but presence of end-organ damage defines disease (not absolute blood pressure number)
** CV - MI, CHF/LV failure/pulm edema, aortic dissection
**1%-6% of all ED patients will present with severe hypertension, but less than half of those will have target organ damage<ref>Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252. doi:10.1161/01.HYP.0000107251.49515.c2</ref>
** Renal - Acute failure, hematuria, proteinuria
* Ancillary Tests
** Chemistry - assess renal failure
** UA - Assess renal failure, glomerulo nephritis, preeclampsia
** Troponin
** CXR - Evidenceo failure, dissection
** ECG


==Etiology==
===Etiology===
*Idiopathic
*[[Sympathomimetic]] drug use
*[[Preeclampsia]]
*Acute [[glomerulonephritis]]


* Idiopathic
===Prehospital===
* Sympathomimetic drug use
*Prehospital BP measurements should be considered reliable<ref>Cienki JJ, DeLuca LA. Agreement between emergency medical services and expert blood pressure measurements. J. Emerg Med. 2012;43(1):64-68.</ref>
* Preeclampsia
*Acute lowering of BP is not typically recommended
* Acute glomerulonephritis
*Focus on ABCs (assess need for [[intubation]] or [[BiPAP|respiratory support]])
*Provide care of treatable etiologies
**[[CHF]]
**[[Respiratory failure]] from [[pulmonary edema]]
**Acute pain


==Treatment==
==Clinical Features==
'''End-Organ Dysfunction<ref>Levy PD. Hypertensive Emergencies — On the Cutting Edge. EMCREG - International. 2011. 19-26.</ref>'''
*[[Acute kidney injury]]
**Often with microscopic hematuria
*[[Pulmonary edema]]
*Type-II [[myocardial infarction]]
*[[Hypertensive encephalopathy]]
**Visual disturbances
**[[Seizure]]
**Delirium


* Goal: Lower diastolic pressure to 105mmHg within 2-6 hours
==Differential Diagnosis==
** Maximum initial fall in BP should not exceed 25% of presenting value
{{Hypertension DDX}}
* Be careful of lowering BP in pts with CVA!


{| style="width: 100%" border="1"
==Evaluation==
| Drug
===Workup===
| Dose
''Consider any of the following based on the patient's clinical presentation''<ref>2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925-1938.</ref>
| Mechanism
*CBC with peripheral smear- assess for microangiopathic hemolytic anemia
| Pros
*Chem 8 - assess renal failure and possible secondary causes
| Cons
*[[Troponin|Cardiac enzymes]]
| Notes
*[[Urinalysis]] - Assess renal failure, glomerulonephritis, preeclampsia
*[[ECG]] - [[LVH]], [[myocardial ischemia|ischemia]]
*[[Ultrasound]] - evaluate for aortic dissection, bladder outlet obstruction, or depressed myocardial function
*[[Fundoscopic Exam]] - evaluate for hypertensive retinopathy or papilledema
*[[CXR]] - evaluate for pulmonary edema or dissection
*[[CT head]] - in hypertensive encephalopathy, may not show acute hemorrhage or other acute pathology
**Hypertensive encephalopathy is thought to be secondary to alteration in cerebral auto-regulation leading to [[posterior reversible encephalopathy syndrome]] (now called reversible posterior leukoencephalopathy). Most patients will show changes on MRI, although this is not necessarily indicated in the emergency department.
 
===Diagnosis===
*Must have evidence of end-organ dysfunction
**''High blood pressure without symptoms is NOT hypertensive emergency (see [[asymptomatic hypertension]])''
**''Symptoms such as headache, epistaxis and dizziness are not evidence of acute end-organ damage and they are not indication for acute BP reduction''
 
==Management==
'''High blood pressure without end organ damage is NOT hypertensive emergency (see [[asymptomatic hypertension]])'''
*Goal: Lower mean arterial or systolic pressure by no more than 10-20% in the first hour<ref>Elliott WJ. Clinical features in the management of selected hypertensive emergencies. Prog Cardiovasc Dis. 2006;48(5):316-325. doi:10.1016/j.pcad.2006.02.004</ref>
**Then lower by an additional 5-15% over the next 23 hours for no more than 25% in the first 24 hours
**Exception is [[aortic dissection]] which requires rapid reduction to systolic BP to 100-120 mmHg
*Be careful of lowering BP in patients with [[CVA]]
 
===By Drug===
{| class="wikitable"
|-
| '''Drug'''
| '''Dose'''
| '''Mechanism'''
| '''Pros'''
| '''Cons'''
| '''Notes'''
|-
|-
| Nitroprusside
| [[Nitroprusside]]
|
|  
0.25-8 ?g/kg/min
 
0.3-0.5 mcg/kg/min IV initial infusion
 
Increase by 0.5 mcg/kg/min up to 2mcg/kg/min
 


(start at 0.25)
| Arterial > venodilator
| Arterial and veno-dilator
|  
|
1. Very effective
1. Very effective


2. Immediate onset/offset
2. Immediate onset/offset
|
 
|  
1. Cyanide Toxicity
1. Cyanide Toxicity


2. Coronary steal?
2. Coronary steal?


3. Incr HR
3. Increased HR
|
 
|  
1. Avoid in liver/renal failure
1. Avoid in liver/renal failure


2. Avoid with incr ICP
2. Avoid with increased ICP


3. Avoid in pregnancy
3. Avoid in pregnancy
|-
|-
| Nitgroglycerin
| [[Nitroglycerin]]
| 5-100 ?g/min
| Start 5-100 mcg/min
| Veno>arteriodilation
| Veno>arteriodilation
|
|  
1. Rapid on/offset
1. Rapid on/offset


2. Increases coronary flow
2. Increases coronary flow
| Causes Tachycardia
|
Drug of choice in pts w/ cardiac ischemia,


LV dysfunction, and pulm edema
| Causes tachycardia
|
Drug of choice in patients with cardiac ischemia,
 
LV dysfunction, or pulmonary edema
 
|-
|-
| Labetalol
| [[Labetalol]]
|
|  
20-80mg IV bolus q10min OR
20-80mg IV bolus q10 min '''OR'''


0.5-2mg/min IV
0.5-2 mg/min IV infusion or
| Beta>alpha blocker
 
|
200mg to 400mg PO BID
 
| Beta>α-blocker
|  
1. No change in HR, cerebral flow
1. No change in HR, cerebral flow
2. Rapid onset


2. Rapid onset
|  
|
Avoid in COPD, CHF and heart block
Avoid in COPD, CHF


heart block
|  
|
1. Consider in ACS
1. Consider in ACS
2. Consider in ischemic CVA


2. Consider in ischemic CVA
|-
|-
| Esmolol
| [[Esmolol]]
|
|  
250-500 ?g/kg/min;
Load 250-500 mcg/kg over 2min


may repeat bolus after
Infuse 50 mcg/kg/min over 4min
 
- if ineffective repeat load, increase infusion rate by &nbsp;50mcg/kg/min up to 300mcg/kg/min


5min or incr to 300 ?g/min
| Beta selective
| Beta selective
| 1. Rapid on/offset
| Rapid on/offset
|
|  
Avoid in COPD, CHF
Avoid in COPD, CHF


bradycardia
bradycardia
|
 
|  
Consider in ACS
Consider in ACS
|-
|-
| Nicardipine
| [[Nicardipine]]
| 5-15mg/h<br /><br />
|  
| Decreases PVR<br /><br />
Start 5mg/h
 
If ineffective after 15min increased in 2.5mg/hr interval up to 15mg/hr
 
| Decreases PVR<br/><br/>
| Good for intracranial pathology
| Good for intracranial pathology
| Slower onset/offset
| Slower onset/offset
| Avoid in CHF, ACS
| Avoid in CHF, ACS
|-
|-
| Hydralazine
| [[Phentolamine]]
| 5-10mg IV bolus, max dose 20mg OR 0.5-1mg/min IV infusion
|  
| Arteriolar vasodilator
5-15mg IV bolus q5-15min '''OR'''
| Rarely causes hypotension
 
| Avoid in CAD
0.2-0.5mg/min IV infusion
| Primarily used in pregancy
|-
| Phentolamine
|
5-10mg IV bolus q5-15min OR


0.2-5mg/min IV infusion
| α-blocker
| Alpha blocker
|  
|
|  
|
| Used for catecholamine-induced hypertension
| Used for catecholamine-induced HTN
|-
|-
| Enalapril
| [[Enalaprilat]]
| 1.25mg over 5min q6hr
| Bolus 1.25mg over 5min q6hr, titrate at 30min intervals to max of 5mg q6hr
| Decreases HR, SV, systemic arterial pressure
| Decreases HR, SV, systemic arterial pressure
| Does not impair cerebral flow
| Does not impair cerebral flow
| Variable response
| Variable response
|
|  
1. Used in pts at risk for cerebral hypotension, CHF
1. Used in patients at risk for cerebral hypotension, CHF


2. Avoid in pregnancy
2. Avoid in pregnancy
|}


==Disease Specific==
|-
| [[Clonidine]]
|
0.1 - 0.3 mg PO q12 scheduled; For hypertensive emergency, 0.2 mg x1, then 0.1 mg q1 hr PRN, max 0.6 mg total


===HTN Encephalopathy===
| α-2 agonist, BP effects within 30-60 min after PO dose
|
|
| Reduced CNS sympathetic flow, decreasing SVR, HR, BP; no renal blood flow changes; tolerance/tachyphylaxis develop quickly


Controlled redxn of BP over 1h; never < 110 diastolic


Labetolol, nicardipine, fenoldopam; nitroprusside of diastolic > 140
|-
| [[Hydralazine]]
|
10 - 20 mg slow IV/IM bolus q4-6 hr PRN, max 40 mg/dose


===Stroke===
| Peripheral vasodilator, with fall in BP beginning within 30 min, lasting 2-4 hrs
|
|
| Decrease in DBP > SBP; has increased HR, stroke volume and cardiac outpt; preferential vasodilation > venodilation


10-15% reduction of MAP; diastolic not < 110


lower to 185/110 in ischemic stroke to meet t-PA criteria
|}
 
Labetolol, nicardipine, nitroprusside as above
 
===Acute Aortic Dissection===
 
Rapid redxn of BP, systolic bp 100-120; HR 60-80 ''within'' 20mins
 
Prevent reflex tachycardia
 
Nitroprusside, fenoldopam, nicardipine ''with'' metoprolol or esmolol; labetolol alone
 
===ACS and Pulmonary Edema===
 
Nitroglycerin
 
Eslampsia/Pre-eclampsia
 
Labetolol, nicardipine or IV hydralazine
 
Magnesium
 
Cocaine and Amphetamine Toxicitiy
 
BDZs
 
Mixed alpha + B blockade: phentolamine or nitroprusside ''plus'' beta blocker
 
===Pheochromocytoma===
 
Phentolamine or nitroprusside ''plus'' beta blocker
 
===ARF===
 
Fenoldopam, nicardipine; nitroprusside risk cyanide toxicity (renal metabolism)
 
==Source==
 
Adapted from Bessen, Bresler (ACEP '09), UpT
 
 
 
==Diagnosis==
 
 
* End-organ damage 2/2 increased BP (generally >180/120, usually > 220/130)
* Brain - Encephelopathy, seizure, ICH, ischemic stroke
* Eyes - Retinal hemorrhage, exudate, papilledema
* CV - MI, CHF/LV failure/pulm edema, aortic dissection
* Renal - Acute failure, hematuria, proteinuria
* Ancillary Tests
* Chemistry - assess renal failure
* UA - Assess renal failure, glomerulo nephritis, preeclampsia
* Troponin
* CXR - Evidenceo failure, dissection
* ECG
 
==Etiology==
 
 
* Idiopathic
* Sympathomimetic drug use
* Preeclampsia
* Acute glomerulonephritis
 
Treatment
 
* Goal: Lower diastolic pressure to 105mmHg within 2-6 hours
* Maximum initial fall in BP should not exceed 25% of presenting value
* Be careful of lowering BP in pts with CVA!
 
Drug Dose Mechanism Pros Cons Notes
Nitroprusside 0.25-8µg/kg/min
 
(start at 0.25)
 
Arterial and veno-dilator 1. Very effective
 
2. Immediate onset/offset
 
1. Cyanide Toxicity
 
2. Coronary steal?
 
3. Incr HR
 
1. Avoid in liver/renal failure
 
2. Avoid with incr ICP
 
3. Avoid in pregnancy
 
Nitgroglycerin 5-100 µg/min Veno>arteriodilation 1. Rapid on/offset
 
2.  Increases coronary flow
 
Causes Tachycardia Drug of choice in pts w/ cardiac ischemia,
 
LV dysfunction, and pulm edema
 
Labetalol 20-80mg IV bolus q10min OR
 
0.5-2mg/min IV
 
Beta>alpha blocker 1. No change in HR, cerebral flow
 
2. Rapid onset
 
Avoid in COPD, CHF
 
heart block
 
1. Consider in ACS
 
2. Consider in ischemic CVA
 
 
Esmolol 250-500 µg/kg/min;
 
may repeat bolus after
 
5min or incr to 300µg/min
 
Beta selective 1. Rapid on/offset Avoid in COPD, CHF
 
bradycardia
 
Consider in ACS
 
Nicardipine  5-15mg/h Decreases PVR Good for intracranial pathology Slower onset/offset Avoid in CHF, ACS
Hydralazine 5-10mg IV bolus, max dose 20mg OR 0.5-1mg/min IV infusion Arteriolar vasodilator Rarely causes hypotension Avoid in CAD Primarily used in pregancy
Phentolamine 5-10mg IV bolus q5-15min OR
 
0.2-5mg/min IV infusion
 
Alpha blocker Used for catecholamine-induced HTN
Enalapril 1.25mg over 5min q6hr Decreases HR, SV, systemic arterial pressure Does not impair cerebral flow Variable response 1. Used in pts at risk for cerebral hypotension, CHF
 
2. Avoid in pregnancy
 
Disease Specific
 
HTN Encephalopathy
 
    Controlled redxn of BP over 1h; never < 110 diastolic
 
          Labetolol, nicardipine, fenoldopam; nitroprusside of diastolic > 140
 
 
Stroke
 
    10-15% reduction of MAP; diastolic not < 110
 
    lower to 185/110 in ischemic stroke to meet t-PA criteria
 
          Labetolol, nicardipine, nitroprusside as above
 
 
Acute Aortic Dissection
 
    Rapid redxn of BP, systolic bp 100-120; HR 60-80 within 20mins
 
    Prevent reflex tachycardia
 
          Nitroprusside, fenoldopam, nicardipine with metoprolol or esmolol; labetolol alone
 
 
ACS and Pulmonary Edema
 
    Nitroglycerin


===By Disease===


Eslampsia/Pre-eclampsia
====[[Aortic Dissection]]====


    Labetolol, nicardipine or IV hydralazine
*Rapidly reduce sys BP to 100-120; HR 60-80 within 20min
*Adequate analgesia will decrease sympathetic drive and assist with BP and HR control
*Avoid volume depletion
*Prevent reflex tachycardia
**Labetalol alone
**Nitroprusside or nicardipine AFTER metoprolol or esmolol


    Magnesium
====[[Pulmonary Edema]]====
*Reduce BP by 20-30%
*Promote diuresis AFTER vasodilation


====[[ACS]]====


Cocaine and Amphetamine Toxicitiy
*No more than 20-30% reduction for SBP >160
*Consider NTG, beta-blocker


    BDZs
====[[Cocaine]]/[[Amphetamine]] Toxicitiy====


    Mixed alpha + B blockade: phentolamine or nitroprusside plus beta blocker
*[[Benzos]]
*Mixed α + B blockade
**Phentolamine '''OR''' nitroprusside AND β-blocker


====[[Renal Failure]]====


Pheochromocytoma
*Reduce BP by no more than 20%
*Avoid nitroprusside (renal metabolism)
*Labetalol or nicardipine


    Phentolamine or nitroprusside plus beta blocker
====[[Eclampsia]]/[[Pre-eclampsia]]====


*Goal BP <160/110
*Labetalol or nicardipine
*Magnesium


ARF
====[[Hypertensive emergency]]====
*Decrease MAP by 15-20%
**Avoid overly aggressive lowering
*[[Nicardipine]] or [[labetalol]]


    Fenoldopam, nicardipine; nitroprusside risk cyanide toxicity (renal metabolism)
====[[CVA]]====


*[[SAH]]
**See [[Subarachnoid Hemorrhage (SAH)]]
*[[ICH]]
*See [[ICH#Guidelines|current guidelines]] for best practice
**[[Labetalol]] or [[Nicardipine]] or [[Esmolol]]
*[[Stroke (Main)|Ischemic]]
**If thrombolytic treatment is planned then goal systolic blood pressure 185 mm Hg and diastolic blood pressure 110 mm Hg<ref>Acute Stroke Practice Guidelines for Inpatient Management of Ischemic
Stroke and Transient Ischemic Attack (TIA) https://www.heart.org/idc/groups/heart-public/@wcm/@private/@hcm/documents/downloadable/ucm_309996.pdf</ref>
**If no thrombolytics then consider blood pressure control if SBP >220 mmHg or DBP >120 mmgHg
**[[Labetalol]] or [[Nicardipine]] are both effective and safe


Source
====[[Pheochromocytoma]]====
*Phentolamine '''OR''' (nitroprusside AND β-blocker)


Adapted from Bessen, Bresler (ACEP '09), UpToDate
==Disposition==
*Admit
**Patients receiving titratable antihypertensive therapies will likely require admission to critical care unit


==See Also==
*[[Hypertension (main)]]
*[[Asymptomatic hypertension]]
*[[IV nitroglycerine alternatives]]


==External Links==
*[http://www.emdocs.net/hypertensive-crisis-pearls-and-pitfalls-for-the-ed-physician/ emDocs - Hypertensive Emergency: Pearls and Pitfalls for the ED Physician]
*[https://emcrit.org/ibcc/hypertensive-emergency/ EMCrit - Hypertensive Emergency]


==References==
<references/>


[[Category:Cards]]
[[Category:Cardiology]]

Latest revision as of 20:09, 17 April 2024

High blood pressure without symptoms is NOT hypertensive emergency (see asymptomatic hypertension)

Background

  • Definition: end-organ damage due to hypertension
    • Blood pressure is generally >180/120 (usually > 220/130), but presence of end-organ damage defines disease (not absolute blood pressure number)
    • 1%-6% of all ED patients will present with severe hypertension, but less than half of those will have target organ damage[1]

Etiology

Prehospital

Clinical Features

End-Organ Dysfunction[3]

Differential Diagnosis

Hypertension

Evaluation

Workup

Consider any of the following based on the patient's clinical presentation[4]

  • CBC with peripheral smear- assess for microangiopathic hemolytic anemia
  • Chem 8 - assess renal failure and possible secondary causes
  • Cardiac enzymes
  • Urinalysis - Assess renal failure, glomerulonephritis, preeclampsia
  • ECG - LVH, ischemia
  • Ultrasound - evaluate for aortic dissection, bladder outlet obstruction, or depressed myocardial function
  • Fundoscopic Exam - evaluate for hypertensive retinopathy or papilledema
  • CXR - evaluate for pulmonary edema or dissection
  • CT head - in hypertensive encephalopathy, may not show acute hemorrhage or other acute pathology
    • Hypertensive encephalopathy is thought to be secondary to alteration in cerebral auto-regulation leading to posterior reversible encephalopathy syndrome (now called reversible posterior leukoencephalopathy). Most patients will show changes on MRI, although this is not necessarily indicated in the emergency department.

Diagnosis

  • Must have evidence of end-organ dysfunction
    • High blood pressure without symptoms is NOT hypertensive emergency (see asymptomatic hypertension)
    • Symptoms such as headache, epistaxis and dizziness are not evidence of acute end-organ damage and they are not indication for acute BP reduction

Management

High blood pressure without end organ damage is NOT hypertensive emergency (see asymptomatic hypertension)

  • Goal: Lower mean arterial or systolic pressure by no more than 10-20% in the first hour[5]
    • Then lower by an additional 5-15% over the next 23 hours for no more than 25% in the first 24 hours
    • Exception is aortic dissection which requires rapid reduction to systolic BP to 100-120 mmHg
  • Be careful of lowering BP in patients with CVA

By Drug

Drug Dose Mechanism Pros Cons Notes
Nitroprusside

0.3-0.5 mcg/kg/min IV initial infusion

Increase by 0.5 mcg/kg/min up to 2mcg/kg/min


Arterial > venodilator

1. Very effective

2. Immediate onset/offset

1. Cyanide Toxicity

2. Coronary steal?

3. Increased HR

1. Avoid in liver/renal failure

2. Avoid with increased ICP

3. Avoid in pregnancy

Nitroglycerin Start 5-100 mcg/min Veno>arteriodilation

1. Rapid on/offset

2. Increases coronary flow

Causes tachycardia

Drug of choice in patients with cardiac ischemia,

LV dysfunction, or pulmonary edema

Labetalol

20-80mg IV bolus q10 min OR

0.5-2 mg/min IV infusion or

200mg to 400mg PO BID

Beta>α-blocker

1. No change in HR, cerebral flow 2. Rapid onset

Avoid in COPD, CHF and heart block

1. Consider in ACS 2. Consider in ischemic CVA

Esmolol

Load 250-500 mcg/kg over 2min

Infuse 50 mcg/kg/min over 4min

- if ineffective repeat load, increase infusion rate by  50mcg/kg/min up to 300mcg/kg/min

Beta selective Rapid on/offset

Avoid in COPD, CHF

bradycardia

Consider in ACS

Nicardipine

Start 5mg/h

If ineffective after 15min increased in 2.5mg/hr interval up to 15mg/hr

Decreases PVR

Good for intracranial pathology Slower onset/offset Avoid in CHF, ACS
Phentolamine

5-15mg IV bolus q5-15min OR

0.2-0.5mg/min IV infusion

α-blocker Used for catecholamine-induced hypertension
Enalaprilat Bolus 1.25mg over 5min q6hr, titrate at 30min intervals to max of 5mg q6hr Decreases HR, SV, systemic arterial pressure Does not impair cerebral flow Variable response

1. Used in patients at risk for cerebral hypotension, CHF

2. Avoid in pregnancy

Clonidine

0.1 - 0.3 mg PO q12 scheduled; For hypertensive emergency, 0.2 mg x1, then 0.1 mg q1 hr PRN, max 0.6 mg total

α-2 agonist, BP effects within 30-60 min after PO dose Reduced CNS sympathetic flow, decreasing SVR, HR, BP; no renal blood flow changes; tolerance/tachyphylaxis develop quickly


Hydralazine

10 - 20 mg slow IV/IM bolus q4-6 hr PRN, max 40 mg/dose

Peripheral vasodilator, with fall in BP beginning within 30 min, lasting 2-4 hrs Decrease in DBP > SBP; has increased HR, stroke volume and cardiac outpt; preferential vasodilation > venodilation


By Disease

Aortic Dissection

  • Rapidly reduce sys BP to 100-120; HR 60-80 within 20min
  • Adequate analgesia will decrease sympathetic drive and assist with BP and HR control
  • Avoid volume depletion
  • Prevent reflex tachycardia
    • Labetalol alone
    • Nitroprusside or nicardipine AFTER metoprolol or esmolol

Pulmonary Edema

  • Reduce BP by 20-30%
  • Promote diuresis AFTER vasodilation

ACS

  • No more than 20-30% reduction for SBP >160
  • Consider NTG, beta-blocker

Cocaine/Amphetamine Toxicitiy

  • Benzos
  • Mixed α + B blockade
    • Phentolamine OR nitroprusside AND β-blocker

Renal Failure

  • Reduce BP by no more than 20%
  • Avoid nitroprusside (renal metabolism)
  • Labetalol or nicardipine

Eclampsia/Pre-eclampsia

  • Goal BP <160/110
  • Labetalol or nicardipine
  • Magnesium

Hypertensive emergency

CVA

Pheochromocytoma

  • Phentolamine OR (nitroprusside AND β-blocker)

Disposition

  • Admit
    • Patients receiving titratable antihypertensive therapies will likely require admission to critical care unit

See Also

External Links

References

  1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252. doi:10.1161/01.HYP.0000107251.49515.c2
  2. Cienki JJ, DeLuca LA. Agreement between emergency medical services and expert blood pressure measurements. J. Emerg Med. 2012;43(1):64-68.
  3. Levy PD. Hypertensive Emergencies — On the Cutting Edge. EMCREG - International. 2011. 19-26.
  4. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925-1938.
  5. Elliott WJ. Clinical features in the management of selected hypertensive emergencies. Prog Cardiovasc Dis. 2006;48(5):316-325. doi:10.1016/j.pcad.2006.02.004
  6. Acute Stroke Practice Guidelines for Inpatient Management of Ischemic Stroke and Transient Ischemic Attack (TIA) https://www.heart.org/idc/groups/heart-public/@wcm/@private/@hcm/documents/downloadable/ucm_309996.pdf